Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors

Prostate

Volumn 73, Issue 13, 2013, Pages 1470-1482

  Wu, Yue ^a   Godoy, Alejandro ^a,b   Azzouni, Faris ^a   Wilton, John H ^a   Ip, Clement ^a   Mohler, James L ^a,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

androgen receptor; dihydrotestosterone; dutasteride; finasteride; prostate cancer; steroid 5 reductase; testosterone

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; ISOENZYME; LUCIFERASE; TESTOSTERONE;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG INHIBITION; HORMONE TRANSPORT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MODULATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANDROGEN RECEPTOR; DIHYDROTESTOSTERONE; DUTASTERIDE; FINASTERIDE; PROSTATE CANCER; STEROID 5Α-REDUCTASE; TESTOSTERONE;

5-ALPHA REDUCTASE INHIBITORS; AZASTEROIDS; CELL LINE, TUMOR; DIHYDROTESTOSTERONE; FINASTERIDE; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TESTOSTERONE;

EID: 84882251884     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22694     Document Type: Article

References (38)

1. Dorsam J, Altwein J,. 5alpha-Reductase inhibitor treatment of prostatic diseases: Background and practical implications. Prostate Cancer Prostatic Dis 2009; 12 (2): 130-136.
2. Russell DW, Wilson JD,. Steroid 5 alpha-reductase: Two genes/two enzymes. Annu Rev Biochem 1994; 63: 25-61.
3. Askew EB, Gampe RT Jr, Stanley TB, Faggart JL, Wilson EM,. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 2007; 282 (35): 25801-25816.
4. Wilson EM, French FS,. Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. J Biol Chem 1976; 251 (18): 5620-5629.
5. Mohler JL,. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 2008; 617: 223-234.
6. Mohler JL,. A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab 2008; 22 (2): 357-372.
7. Azzouni F, Godoy A, Li Y, Mohler J,. The 5 alpha-reductase isozyme family: A review of basic biology and their role in human diseases. Adv Urol 2012; 2012: 530121.
8. Godoy A, Kawinski E, Li Y, Oka D, Alexiev B, Azzouni F, Titus MA, Mohler JL,. 5alpha-reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression. Prostate 2011; 71 (10): 1033-1046.
9. Faller B, Farley D, Nick H,. Finasteride: A slow-binding 5 alpha-reductase inhibitor. Biochemistry 1993; 32 (21): 5705-5710.
10. Tian G, Stuart JD, Moss ML, Domanico PL, Bramson HN, Patel IR, Kadwell SH, Overton LK, Kost TA, Mook RA Jr, Frye SV, Batchelor KW, Wiseman JS,. 17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1. Biochemistry 1994; 33 (8): 2291-2296.
11. Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS,. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004; 172 (3): 915-919.
12. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S,. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89 (5): 2179-2184.
13. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E,. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74 (3): 505-508.
14. Span PN, Voller MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, Kirby RS,. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol 1999; 161 (1): 332-337.
15. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr., The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349 (3): 215-224.
16. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, Group RS,. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362 (13): 1192-1202.
17. Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS,. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 2004; 58 (2): 130-144.
18. Wu Y, Chhipa RR, Zhang H, Ip C,. The antiandrogenic effect of finasteride against a mutant androgen receptor. Cancer Biol Ther 2011; 11 (10): 902-909.
19. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP,. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43 (4): 1809-1818.
20. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW,. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer 1994; 57 (3): 406-412.
21. Godoy A, Watts A, Sotomayor P, Montecinos VP, Huss WJ, Onate SA, Smith GJ,. Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology 2008; 149 (6): 2959-2969.
22. Roth M, Obaidat A, Hagenbuch B,. OATPs, OATs and OCTs: The organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 2012; 165 (5): 1260-1287.
23. Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD,. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008; 14 (11): 3312-3318.
24. Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, Gulley JL, Price DK, Dahut WL, Figg WD,. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int 2008; 102 (5): 617-621.
25. Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R, Stanford JL, Mostaghel EA,. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev 2011; 20 (4): 619-627.
26. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW,. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2011; 29 (18): 2565-2573.
27. Belanger B, Belanger A, Labrie F, Dupont A, Cusan L, Monfette G,. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: Unique importance of extratesticular androgens in men. J Steroid Biochem 1989; 32 (5): 695-698.
28. Morote J, Orsola A, Planas J, Trilla E, Raventos CX, Cecchini L, Catalan R,. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178 (4 Pt 1): 1290-1295.
29. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI,. Reassessment of the definition of castrate levels of testosterone: Implications for clinical decision making. Urology 2000; 56 (6): 1021-1024.
30. Sharifi R, Browneller R, Leuprolide Study Group. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol 2002; 168 (3): 1001-1004.
31. Chouinard S, Pelletier G, Belanger A, Barbier O,. Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium. Endocr Res 2004; 30 (4): 717-725.
32. Barbier O, Belanger A,. Inactivation of androgens by UDP- glucuronosyltransferases in the human prostate. Best Pract Res Clin Endocrinol Metab 2008; 22 (2): 259-270.
33. Chouinard S, Barbier O, Belanger A,. UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. J Biol Chem 2007; 282 (46): 33466-33474.
34. Chouinard S, Yueh MF, Tukey RH, Giton F, Fiet J, Pelletier G, Barbier O, Belanger A,. Inactivation by UDP-glucuronosyltransferase enzymes: The end of androgen signaling. J Steroid Biochem Mol Biol 2008; 109 (3-5): 247-253.
35. Levesque E, Beaulieu M, Green MD, Tephly TR, Belanger A, Hum DW,. Isolation and characterization of UGT2B15(Y85): A UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 1997; 7 (4): 317-325.
36. MacLeod SL, Nowell S, Plaxco J, Lang NP,. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Ann Surg Oncol 2000; 7 (10): 777-782.
37. Okugi H, Nakazato H, Matsui H, Ohtake N, Nakata S, Suzuki K,. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population. Cancer Detect Prev 2006; 30 (3): 262-268.
38. Park J, Chen L, Shade K, Lazarus P, Seigne J, Patterson S, Helal M, Pow-Sang J,. Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J Urol 2004; 171 (6 Pt 1): 2484-2488.